Andrew Feber

Clinical Director of Research and Development

1 past transactions

CanSense

Seed Round in 2023
CanSense develops an inexpensive, scalable, non-invasive blood test for the early detection of bowel and colorectal cancer. The test is designed for use in primary care to enable earlier diagnosis, with the aim of reducing cancer mortality and lowering the burden of unnecessary colonoscopies on healthcare systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.